On May 25, 2023 Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast and gynecological cancers harboring ESR1 mutations, reported an abstract to be presented at the 2023 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting detailing the results of its ELAINE-2 clinical study with longer patient follow-up (Press release, Sermonix Pharmaceuticals, MAY 25, 2023, View Source [SID1234632148]). ASCO (Free ASCO Whitepaper) 2023 will be held June 2-6 at McCormick Place in Chicago.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ELAINE-2 (NCT04432454), an open-label, Phase 2 Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE) study of Sermonix’s lead investigational drug, lasofoxifene, in combination with Eli Lilly and Company’s CDK4/6 inhibitor abemaciclib, evaluated 29 women with ER+/HER- metastatic breast cancer and an ESR1 mutation. The primary endpoint was safety/tolerability, with secondary endpoints including progression-free survival (PFS) and overall response rate (ORR). Earlier ELAINE-2 results were shared at ASCO (Free ASCO Whitepaper) 2022.
With patient follow-up through Jan. 31, 2023, the combination of lasofoxifene and abemaciclib continued to be well-tolerated, with clinically meaningful efficacy in women with ER+/HER- metastatic breast cancer and an ESR1 mutation. The previously reported PFS, a median of 13 months, and ORR of 50% were promising, with longer term follow-up to be provided at ASCO (Free ASCO Whitepaper) 2023. Encouraging Phase 2 monotherapy and combination results in ELAINE-1 and ELAINE-2 respectively led Sermonix in March to initiate ELAINE-3, a confirmatory Phase 3 randomized study. Enrolling 400 patients, ELAINE-3 will again assess the efficacy of the combination of lasofoxifene and abemaciclib compared to the combination of fulvestrant and abemaciclib.
"Sermonix is pleased that the combination of lasofoxifene and abemaciclib, which demonstrated compelling anti-tumor activity in ELAINE-2, continued to be well-tolerated when observed through a longer patient follow-up," said Dr. David Portman, founder and chief executive officer of Sermonix. "The results solidify our team’s excitement for ELAINE-3 enrollment and continue to point to a potential therapy with a favorable safety profile and the ability to address a critical unmet need for women confronted with metastatic breast cancer. We look forward to further discussing the results at ASCO (Free ASCO Whitepaper) 2023."
Details of Sermonix’s ASCO (Free ASCO Whitepaper) 2023 poster presentation are as follows:
Abstract Title: Lasofoxifene (LAS) plus abemaciclib (Abema) for treating ESR1-mutated ER+/HER2- metastatic breast cancer (mBC) after progression on prior therapies: ELAINE 2 study update.
Session Title: Breast Cancer—Metastatic
Session Date and Time: June 4, 2023, 8-11 a.m. CT
Sermonix will also convene meetings of its ELAINE-3 Steering Committee and ELAINE-3 Translational Committee while at ASCO (Free ASCO Whitepaper).
To learn more about Sermonix Pharmaceuticals and lasofoxifene, visit View Source
About Lasofoxifene
Lasofoxifene is an investigational novel endocrine therapy in clinical development which has demonstrated robust target engagement as an ESR1 antagonist in the breast, particularly in the presence of ESR1 mutations. Lasofoxifene has demonstrated anti-tumor activity as monotherapy and in combination with abemaciclib in Phase 2 studies and has unique tissue selectivity distinguishing it from other current and investigational endocrine therapies, with beneficial effects seen on vagina and bone in previous clinical studies. Lasofoxifene, which Sermonix licensed globally from Ligand Pharmaceuticals Inc. (NASDAQ:LGND), has been studied in previous comprehensive Phase 1-3 non-oncology clinical trials in more than 15,000 postmenopausal women worldwide. Lasofoxifene’s bioavailability and activity in mutations of the estrogen receptor could potentially hold promise for patients who have acquired endocrine resistance due to ESR1 mutations, a common finding in the metastatic setting and an area of high unmet medical need. Lasofoxifene’s novel activity in ESR1 mutations was discovered at Duke University and Sermonix has exclusive rights to develop and commercialize the product in this area. Lasofoxifene, a novel targeted and tissue selective oral endocrine therapy could, if approved, play a critical role in the precision medicine treatment of advanced ER+ breast cancer.